Shares of Evoke Pharma Inc. (NASDAQ:EVOK) fell 2.7% during mid-day trading on Thursday . The stock traded as low as $10.02 and last traded at $10.60, with a volume of 95,574 shares. The stock had previously closed at $10.89.

Several brokerages recently issued reports on EVOK. Rodman & Renshaw reissued a “buy” rating and issued a $27.00 price target on shares of Evoke Pharma in a report on Monday, July 11th. FBR & Co reissued a “buy” rating on shares of Evoke Pharma in a report on Friday, July 8th. Brean Capital reaffirmed a “buy” rating on shares of Evoke Pharma in a research note on Friday, July 8th. Finally, Zacks Investment Research downgraded Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Monday, May 16th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $17.47.

The firm’s 50 day moving average is $6.79 and its 200 day moving average is $4.81. The firm’s market cap is $77.69 million.

Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings data on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.04. On average, analysts expect that Evoke Pharma Inc. will post ($1.37) earnings per share for the current fiscal year.

In related news, major shareholder Parters Vii L. P. Domain sold 5,095 shares of the business’s stock in a transaction dated Wednesday, April 27th. The stock was sold at an average price of $5.07, for a total transaction of $25,831.65. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Parters Vii L. P. Domain sold 41,478 shares of the business’s stock in a transaction dated Wednesday, April 20th. The shares were sold at an average price of $5.35, for a total value of $221,907.30. The disclosure for this sale can be found here.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.